Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked conscientiously but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past several shares of mine. The first CytoDyn post of mine, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire interview that I came away with a poor opinion of the company.

Irony of irony, the bad viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the know-how as well as linked intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) and the very first brand new drug application approval ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and many indications, it has this single remedy and a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

Its opening banner on the site of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, several disease types, multiple publications in addition to multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That’s a question I have been asking myself from the really start of the interest of mine in this company. Judging with the multiples of thousands of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *